AIM: To study the in vivo effects of Quin-C1, a highly specific agonist for formyl peptide receptor 2 (FPR2/ALX), in a mouse model of bleomycin (BLM)-induced lung injury. METHODS: Male ICR mice were injected intratracheally with BLM (d 0), and intraperitoneally with Quin-C1 (0.2 mg/d) or vehicle between d 1 and d 28, during which pulmonary inflammation was monitored. A similar regimen was carried out between d 5 and d 28 to differentiate anti-inflammatory from anti-fibrotic effects. During the treatment, leukocyte numbers in bronchoalveolar lavage fluid (BALF) were counted, and FPR2/ALX transcripts, tumor necrosis factor α (TNF-α), interleukin-1β (IL-1β), the mouse keratinocyte-derived chemokine (KC), transforming growth factor β1 (TGF-β1) and C-X-C motif chemokine 10 (CXCL10) expression levels in the lung tissue were also measured. Both hydroxyproline content and histological changes were examined on d 28 to assess the severity of lung fibrosis. RESULTS: BLM caused a significant increase in expression levels of all the selected cytokines and chemokines, as well as a thickening of the alveolar wall. Treatment with Quin-C1 significantly reduced the neutrophil and lymphocyte counts in BALF, diminished expression of TNF-α, IL-1β, KC, and TGF-β1, and decreased collagen deposition in lung tissue. The treatment also lowered the content of lung hydroxyproline. Quin-C1 did not ameliorate lung fibrosis when the treatment was started 5 d after the BLM challenge, suggesting that the protection may be attributed to its anti-inflammatory effects. Exposure to BLM or BLM plus Quin-C1 did not change the level of FPR2/ALX transcripts (mFpr1, mFpr2, and Lxa4r) in the lung tissue. CONCLUSION: The results demonstrate an anti-inflammatory role for Quin-C1 in bleomycin-induced lung injury, which may be further explored for therapeutic applications.
AIM: To study the in vivo effects of Quin-C1, a highly specific agonist for formyl peptide receptor 2 (FPR2/ALX), in a mouse model of bleomycin (BLM)-induced lung injury. METHODS: Male ICR mice were injected intratracheally with BLM (d 0), and intraperitoneally with Quin-C1 (0.2 mg/d) or vehicle between d 1 and d 28, during which pulmonary inflammation was monitored. A similar regimen was carried out between d 5 and d 28 to differentiate anti-inflammatory from anti-fibrotic effects. During the treatment, leukocyte numbers in bronchoalveolar lavage fluid (BALF) were counted, and FPR2/ALX transcripts, tumor necrosis factor α (TNF-α), interleukin-1β (IL-1β), the mouse keratinocyte-derived chemokine (KC), transforming growth factor β1 (TGF-β1) and C-X-C motif chemokine 10 (CXCL10) expression levels in the lung tissue were also measured. Both hydroxyproline content and histological changes were examined on d 28 to assess the severity of lung fibrosis. RESULTS: BLM caused a significant increase in expression levels of all the selected cytokines and chemokines, as well as a thickening of the alveolar wall. Treatment with Quin-C1 significantly reduced the neutrophil and lymphocyte counts in BALF, diminished expression of TNF-α, IL-1β, KC, and TGF-β1, and decreased collagen deposition in lung tissue. The treatment also lowered the content of lung hydroxyproline. Quin-C1 did not ameliorate lung fibrosis when the treatment was started 5 d after the BLM challenge, suggesting that the protection may be attributed to its anti-inflammatory effects. Exposure to BLM or BLM plus Quin-C1 did not change the level of FPR2/ALX transcripts (mFpr1, mFpr2, and Lxa4r) in the lung tissue. CONCLUSION: The results demonstrate an anti-inflammatory role for Quin-C1 in bleomycin-induced lung injury, which may be further explored for therapeutic applications.
Authors: T Okazaki; A Nakao; H Nakano; F Takahashi; K Takahashi; O Shimozato; K Takeda; H Yagita; K Okumura Journal: J Immunol Date: 2001-08-15 Impact factor: 5.422
Authors: Tamara Boltersdorf; Junaid Ansari; Elena Y Senchenkova; Jieny Groeper; Denise Pajonczyk; Shantel A Vital; Gaganpreet Kaur; J Steve Alexander; Thomas Vogl; Ursula Rescher; Nicholas J Long; Felicity N E Gavins Journal: Theranostics Date: 2020-05-17 Impact factor: 11.556
Authors: Madia L Stama; Enza Lacivita; Liliya N Kirpotina; Mauro Niso; Roberto Perrone; Igor A Schepetkin; Mark T Quinn; Marcello Leopoldo Journal: ChemMedChem Date: 2017-11-07 Impact factor: 3.466
Authors: Enza Lacivita; Igor A Schepetkin; Madia L Stama; Liliya N Kirpotina; Nicola A Colabufo; Roberto Perrone; Andrei I Khlebnikov; Mark T Quinn; Marcello Leopoldo Journal: Bioorg Med Chem Date: 2014-12-13 Impact factor: 3.641
Authors: Igor A Schepetkin; Liliya N Kirpotina; Andrei I Khlebnikov; Marcello Leopoldo; Ermelinda Lucente; Enza Lacivita; Paola De Giorgio; Mark T Quinn Journal: Biochem Pharmacol Date: 2012-12-03 Impact factor: 5.858